$43,200.57 speaking Payment -- Novartis Pharmaceuticals to Dr. Paul Turner

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Novartis Pharmaceuticals made a $43.2K speaking payment to Paul Turner, a Dermatology specialist in City, VA. The payment was associated with Xarelto. Dr. Paul Turner received a significant payment of $43,200.57 from Novartis Pharmaceuticals. The payment was for serving as faculty or a speaker, specifically related to Xarelto. This payment represents a substantial amount for a single speaking engagement or faculty role.

Patient Guidance: What This Payment Means for You

If you are a patient, understand that your doctor may receive payments from pharmaceutical companies for educating others about medications like Xarelto. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

This payment for speaking services is on the higher end compared to typical speaking fees in dermatology, suggesting a significant role or extensive engagement.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for speaking engagements are permissible under the Open Payments program, provided they are accurately reported and do not violate anti-kickback statutes.

Related Topics

This payment is related to the following healthcare transparency topics:

• speaking-fees
• pharmaceutical-payments
• speaker-programs
• dermatology
• novartis
• xarelto

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $43.2K payment for?

This was a speaking payment of $43.2K from Novartis Pharmaceuticals to Paul Turner, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Paul Turner accept pharmaceutical money?

Yes, Paul Turner received this $43.2K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $43.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Dermatology?

To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Paul Turner's relationship with Novartis Pharmaceuticals?

The payment amount is notably high for a speaking engagement. This $43.2K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Dermatology?

The payment is tied to a specific drug, Xarelto.

What should patients do after learning about this payment?

If you are a patient, understand that your doctor may receive payments from pharmaceutical companies for educating others about medications like Xarelto.

What else should I know about this speaking payment?

The payment was made by a major pharmaceutical company, Novartis.

Related Reports

• View Dr. Paul Turner's full payment report
• Novartis Pharmaceuticals full spending report
• Browse all Dermatology payments
• Browse all payments in Virginia
• Search for other payments